A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 May 2017
At a glance
- Drugs Bortezomib (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 26 Apr 2015 Planned primary completion date changed from 1 Jun 2014 to 1 Jun 2017 as reported by ClinicalTrials.gov record.
- 06 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 May 2013 Planned end date changed from 1 Jan 2012 to 1 Jun 2014 as reported by ClinicalTrials.gov.